Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 ...

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...
TMCnet

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Comp…

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

Doximity: Strong Quarter Overshadowed By Policy-Driven Budget Uncertainty

Doximity shows strong growth, high margins, solid cash strength and policy-linked guidance challenges shaping near-term ...